TP Therapeutics

Clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases.

Launch date

Apr 2011

Employees

Market cap

Enterprise valuation

CAD5.6b (Public information from Jun 2022)

San Diego California (HQ)

Date	Investors	Amount	Round
-	Harbinger Ventures HBM Partners	N/A	-
Jan 2014	CRCM Ventures	$1.4m	Early VC
Jul 2015	N/A	N/A	Series B
Mar 2016	CRCM Ventures	$18.0m	Late VC
May 2017	SR One OrbiMed SV Tech Ventures Cormorant Asset Management Lilly Asia Ventures	$45.0m	Series C
Oct 2018	SR One Foresite Capital OrbiMed Cormorant Asset Management venBio Partners Lilly Asia Ventures Nextech Invest Kenson Ventures	$80.0m	Series D
Apr 2019	N/A	N/A	IPO
Sep 2019*	N/A	$203m	Post IPO Equity
May 2020*	N/A	$374m	Post IPO Equity
Oct 2020*	N/A	$460m	Post IPO Equity
Jun 2022*	Bristol-Myers Squibb	$4.1b Valuation: $4.1b	Acquisition
Total Funding		CAD197m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about TP Therapeutics